Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
Electrolytes & Blood Pressure
;
: 23-26, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-739604
ABSTRACT
A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Concentration osmolaire
/
Valeurs de référence
/
Sodium
/
Polykystose rénale autosomique dominante
/
Rein
/
Corée
/
Foie
Limites du sujet:
Humains
/
Mâle
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Electrolytes & Blood Pressure
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS